The size of the Global Anti-neoplastic Agents Market is estimated to grow at a CAGR of 8.3% from 2019 to 2024.
Anti-neoplastic Agents are the first line of treatment for cancer. A variety of anti-neoplastic are available in the market and many drugs are still in the clinical phase. Cancer is becoming a major cause of death all over the world.
The rising number of people being diagnosed with cancer and the demand for affordable treatments for the same are the major drivers driving the market growth. Due to the recent advancements in personalized medicines the market is expected to propel during the forecast period.
However, the high manufacturing costs of anti-neoplastic agents is the major factor hampering the Anti-neoplastic Agents Market growth.
Market Size Available
2018 – 2024
2019 - 2024
By Products, End Users and Region
Various Analyses Covered
Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities
North America, Europe, APAC, Latin America, Middle East & Africa
Market Leaders Profiled
Aspen Global Inc., Bayer AG, Teva Pharmaceutical Industries Ltd., Johnson & Johnson Pvt. Ltd., Merc & Co., Inc., Pfize Inc., Hoffmann-La Roche Ltd., Amgen Inc., Bristol-Myers Squibb Company, Baxter Healthcare Corporation, Boehringer Ingelheim GmbH, Accord Healthcare, Inc., Genentech, Inc., Lundbeck LLC, AbbVie Inc.
This research report on the Global Anti-neoplastic Agents Market segmented and sub-segmented into the following categories and analyzed market size and forecast for each segment until 2024.
Anti-neoplastic Agents Market Analysis – By Product:
On the basis of product, the chemotherapeutic agent segment accounts for a major share of the market revenue.
Anti-neoplastic Agents Market Analysis – By End Users:
On the basis of end-users, the Hospital segment dominated a major share of the market revenue.
The Global Anti-neoplastic Agents market was dominated by North America closely followed Europe. Asia Pacific is expected to grow at a high CAGR.
Top companies leading the Global Anti-neoplastic Agents Market profiled in this report are:
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1.2 Chemotherapeutic agent
5.1.3 Biological agents
5.1.4 Personalied medicine
5.1.5 Y-o-Y Growth Analysis, By Product
5.1.6 Market Attractiveness Analysis, By Product
5.1.7 Market Share Analysis, By Product
5.2 End user
5.2.4 Cancer rehabilitaion centers
5.2.5 Ambulatory surgical centers
5.2.6 Y-o-Y Growth Analysis, By end user
5.2.7 Market Attractiveness Analysis, By end user
5.2.8 Market Share Analysis, By end user
6. Geographical Analysis
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
126.96.36.199 By Geographical Area
188.8.131.52 By Product
184.108.40.206 By end user
6.1.4 Market Attractiveness Analysis
220.127.116.11 By Geographical Area
18.104.22.168 By Product
22.214.171.124 By end user
6.1.5 Market Share Analysis
126.96.36.199 By Geographical Area
188.8.131.52 By Product
184.108.40.206 By end user
6.2 North America
6.1.2 United States
6.3.6 South Korea
6.5 Latin America
6.4.5 Rest of Latin America
6.6 Middle East & Africa
7. Strategic Analysis
7.1 PESTLE analysis
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Hoffmann-La Roche Ltd
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Amgen Inc.
8.3 Bristol-Myers Squibb Company
8.4 Baxter Healthcare Corporation
8.5 Boehringer Ingelheim GmbH
8.6 Aspen Global Inc.
8.7 Bayer AG
8.8 Teva pharmaceutical Industries Ltd.
8.9 Johnson & Johnson Pvt. Ltd.
8.10 Accord Healthcare, Inc.
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
a) List of Tables
b) List of Figures